Avacta Group Plc

Equities

AVCT

GB00BYYW9G87

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 11:35:25 2024-04-29 am EDT			5-day change	1st Jan Change
48.3 ^GBX	-1.02%		+8.30%	-58.54%

Apr. 22	First Tin updates Tellerhauser estimates	AN
Apr. 10	Transcript : Avacta Group Plc - Special Call

Avacta Group - Updated Results from Single-Agent Phase 1 Clinical Trial of Peptide Drug Conjugate, AVA6000 to be presented in a Poster at the American Association of Cancer Research Annual Meeting on April 9, 2024

March 07, 2024 at 10:07 am EST

Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, today announces updated clinical data from the First-in-Human Phase 1 trial of the peptide drug conjugate, AVA6000 will be presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting, taking place in San Diego, California from 5-10 April 2024.

The results will be presented in the Phase 1 Clinical Trials 2 Poster Session on April 9, 2024 as detailed below.

Presentation details

Title: A Phase I trial of AVA6000, a Fibroblast Activation Protein (FAP)-released and tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate in patients with FAP-positive solid tumors

Session Title: First-in-Human Phase I Clinical Trials 2

Session Date and Time: Tuesday 9 April 2024 9:00 AM - 12:30 PM

Location: San Diego Convention Center, San Diego CA USA

Abstract Presentation Number: CT188

First Author: Udai Banerji, MD, PhD, The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust

Contact:

Tel: +44 (0)1904 21 7070

Tel: +44 (0)20 3871 9700

Latest news about Avacta Group Plc

First Tin updates Tellerhauser estimates	Apr. 22	AN
Transcript : Avacta Group Plc - Special Call	Apr. 10
Avacta Group plc Reports Data from the Ongoing Phase 1 Clinical Trial of AVA6000 At the AACR Annual Meeting	Apr. 09	CI
Avacta doses third patient in drug conjugate trial for tumour tissue	Mar. 21	AN
Avacta shareholders give AGM go-ahead to issue new shares	Mar. 18	AN
EARNINGS AND TRADING: Harland & Wolff wins major Falklands contract	Mar. 05	AN
Avacta Group Upsizes Share Placement Amid Strong Investor Demand	Feb. 29	MT
Avacta increases placing size to GBP26 million thanks to strong demand	Feb. 29	AN
AIM WINNERS & LOSERS: Beacon Energy and Avacta fall on fundraise	Feb. 29	AN
Avacta plans fundraise to fund clinical development	Feb. 28	AN
Avacta says new head of R&D Coughlin brings "deep expertise"	Jan. 19	AN
Avacta Group plc Announces Appointment of Christina Coughlin as Head of Research and Development and Resignation of Fiona Mclaughlin as Chief Scientific Officer	Jan. 19	CI
Avacta taps biopharma veteran as Therapeutics business chief	Dec. 19	AN
Avacta Group plc Appoints Simon Bennett as Chief Business Officer of the Therapeutics Division	Dec. 19	CI
Avacta says study shows cancer treatment AVA6000 working as planned	Dec. 13	AN
Transcript : Avacta Group Plc - Special Call	Dec. 13
Avacta Group plc Provides Detailed Pre-Clinical, Clinical and Pharmacokinetic Data from the Phase 1A Dose Escalation Study	Dec. 13	CI
Avacta loss widens on cost rise but clinical tests positive	23-09-28	AN
Transcript : Avacta Group Plc, H1 2023 Earnings Call, Sep 28, 2023	23-09-28
Earnings Flash (AVCT.L) AVACTA GROUP Reports H1 Revenue GBP11.9M	23-09-28	MT
Earnings Flash (AVCT.L) AVACTA GROUP Posts H1 Loss GBX-4.28	23-09-28	MT
Avacta Group Plc Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-28	CI
Stocks called up despite China, rate worries	23-09-28	AN
Capital inks contract; Lansdowne becomes cash shell	23-09-20	AN
Avacta Group Plc Announces Management Changes	23-09-20	CI

Chart Avacta Group Plc

Duration

Period

More charts

Company Profile

Avacta Group plc is a United Kingdom-based life sciences company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics. The Company has two segments: Therapeutics and Diagnostics. The Therapeutics segment is a clinical stage oncology biotech division harnessing therapeutic platforms to develop novel, highly targeted cancer drugs. The Diagnostics segment is focused on supporting healthcare professionals and broadening access to diagnostics. It has two platforms: preICISION and Affimer. The Company's preICISION platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The preICISION platform harnesses this tumor specific protease to activate preICISION peptide drug conjugates and preICISION antibody/Affimer drug conjugates in the tumor microenvironment. Its lead preICISION program AVA6000, a peptide drug conjugate form of doxorubicin, is in Phase 1 studies.

Sector

Biotechnology & Medical Research

Calendar

2024-04-29 - Q4 2023 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Avacta Group Plc

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.488 GBP

Average target price

0.9233 GBP

Spread / Average Target

+89.21%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
AVACTA GROUP PLC	-58.54%	216M
VERTEX PHARMACEUTICALS INCORPORATED	-2.62%	103B
REGENERON PHARMACEUTICALS, INC.	+1.75%	95.28B
ARGENX SE	+1.46%	22.15B
BIONTECH SE	-15.71%	21.02B
GENMAB A/S	-8.58%	18.15B
WUXI APPTEC CO., LTD.	-38.74%	16.73B
BEIGENE, LTD.	-13.14%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+4.64%	13.68B
SAREPTA THERAPEUTICS, INC.	+35.30%	12.17B

Bio Therapeutic Drugs